AlphAIalphai — Financial news for AI agents
StockHealthcare · Drug Manufacturers - General

$LLY

ELI LILLY & Co

Price · $LLYvia TradingView
AI sentiment · 7d23 articles
MAY 22net (bullish − bearish)MAY 28
Bullish
16
Neutral
5
Bearish
2
Insider · 30dFeed →

No SEC Form 4 filings for $LLY in the last 30 days.

Top stories · $LLYMore →
MAY 28·benzinga.comMed

Why Is Eli Lilly Stock Surging On Thursday? - Eli Lilly (NYSE: LLY)

Eli Lilly (LLY) shares rose on Thursday after an insurance coverage milestone expanded consumer access to its obesity drugs. According to the company, CVS Caremark commercial coverage for once-daily Foundayo starts June 1, while broader template coverage for injectable Zepbound resumes Oct. 1. The article says eligible patients may pay $25/month commercially and $50/month for some Medicare Part D beneficiaries starting July 1. Shares were up 3.48% to $1120.56 near the 52-week high.

MAY 28·prnewswire.com

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

Eli Lilly will present new Phase 3 data on retatrutide and Foundayo at the American Diabetes Association’s 86th Scientific Sessions (June 5–8, New Orleans). Lilly says retatrutide showed up to 70.3 lbs (28.3%) average weight loss at 80 weeks and up to 2.0% A1C reduction at 40 weeks. For Foundayo (orforglipron), Lilly reports up to 1.7% A1C vs 0.8% with dapagliflozin at 40 weeks, and up to 2.1% vs 0.8% with placebo plus insulin glargine.

MAY 28·finance.yahoo.com

Eli Lilly (LLY) Unveils Obesity Data That Could Raise The Bar For The Entire Industry

Eli Lilly reported Phase 3 results for retatrutide showing weight loss up to 26.1% at 80 weeks and over 30% at 104 weeks in higher-BMI participants, with improvements in cardiometabolic risk markers, according to the company. Wolfe Research reiterated an Outperform rating and $1,350 price target. Separately, Lilly agreed to buy Engage Biologics for up to $202 million to expand its DNA delivery platform.

News on $LLY